Cochrane review (Konghom et al., 2010): no pharmacotherapy with proven efficacy for inhalant use disorder
No FDA-approved treatment for inhalant use disorder
Catecholamine avoidance is the critical therapeutic principle
All sympathomimetics contraindicated in acute setting
Epinephrine — absolute contraindication in suspected inhalant-related VF
Norepinephrine — relative contraindication, use only if no alternative for refractory shock
AHA 2025 CPR guidelines: avoidance of epinephrine in hydrocarbon-mediated arrhythmia
Beta-blockade for arrhythmia
Theoretical basis: block catecholamine sensitization of myocardium
Evidence is based on animal models and case reports (not RCTs)
Esmolol preferred (short half-life, titratable)
Electrolyte disturbances are critical therapeutic targets
Toluene hypokalemia: aggressive potassium repletion before cardiac arrest risk
Monitor ECG continuously during repletion
Long-term treatment
Cognitive behavioral therapy — most evidence-supported psychological intervention
Multisystemic therapy — evidence in adolescent populations
Community-based prevention and supply reduction programs
Patient Discharge Instructions
copy discharge instructions
What is inhalant abuse?
Inhalant abuse means intentionally breathing chemical fumes from household products to get high
Common products include paint thinner, glue, aerosol sprays, keyboard dusters, and gasoline
These chemicals can cause sudden death even with the very first time they are used
Why is this so dangerous?
Inhalants cause sudden cardiac arrest (sudden sniffing death syndrome) without warning
This can happen with the very first use and during any subsequent use
Standard drug tests will not detect inhalants, so a normal drug test does not mean it is safe
Return to the emergency department immediately if you experience any of the following
Chest pain, pounding heartbeat, or irregular heartbeat
Fainting or loss of consciousness
Difficulty breathing or shortness of breath
Severe muscle weakness or inability to walk
Confusion, severe headache, or inability to be roused
Dark brown or tea-colored urine (sign of muscle breakdown)
Any return of symptoms after leaving the emergency department
Medications and activity after discharge
Do not use any inhalants, solvents, or aerosol sprays intentionally
Do not combine inhalants with alcohol or any other substances
Rest and increase fluid intake over the next 24–48 hours
Follow-up with your family doctor or addiction medicine specialist within 1–2 weeks
For parents and caregivers
Secure household chemicals and aerosol products to reduce access
Learn warning signs: chemical odor on breath or clothing, paint stains, empty aerosol cans
Inhalant abuse is not detected on standard school or workplace drug tests
Speak with a healthcare provider or addiction specialist about prevention resources
References
Guidelines and key sources
Anderson CE, Loomis GA. Recognition and Prevention of Inhalant Abuse. American Family Physician. 2003. PMID 13678134
Epidemiology, methods of use, pregnancy risks, prevention strategies
Ford JB, Sutter ME, Owen KP, Albertson TE. Volatile Substance Misuse: An Updated Review of Toxicity and Treatment. Clinical Reviews in Allergy and Immunology. 2014. PMID 23649409
Comprehensive toxicology review, organ systems, physical exam findings, clinical management
Tormoehlen LM, Tekulve KJ, Nangas KA. Hydrocarbon Toxicity: A Review. Clinical Toxicology. 2014. PMID 24911841
Berling I, Isbister GK. Rare but Relevant: Hydrocarbons and Sudden Sniffing Syndrome. Addiction. 2025. PMID 40275758
Mechanism of sudden sniffing death; rapid onset and recovery data
Berling I, Chiew A, Brown J. Poisonings from Hydrocarbon Inhalant Misuse in Australia. Addiction. 2023. PMID 36776135
Epidemiology and acute outcomes in ambulance attendance cohort
Streicher HZ, Gabow PA, Moss AH, Kono D, Kaehny WD. Syndromes of Toluene Sniffing in Adults. Annals of Internal Medicine. 1981. PMID 7235417
Classic paper: toluene-RTA, mean K+ 1.7 mmol/L, electrolyte derangements
Fogelson B, Qu D, Bhagat M, Branca PR. Multi-Organ System Failure Secondary to Difluoroethane Toxicity in a Patient Huffing Air Duster. Journal of Addictive Diseases. 2022. PMID 35044291
Multi-organ failure from keyboard duster (1,1-difluoroethane); electrolyte findings
Konghom S, Verachai V, Srisurapanont M, et al. Treatment for Inhalant Dependence and Abuse. Cochrane Database of Systematic Reviews. 2010
No pharmacotherapy with proven efficacy; basis for supportive-only treatment recommendation
Cairney S, O'Connor N, Dingwall KM, et al. A Prospective Study of Neurocognitive Changes 15 Years After Chronic Inhalant Abuse. Addiction. 2013. PMID 23490054
Long-term neurocognitive sequelae; partial recovery with prolonged abstinence
Cao D, Arens AM, Chow SL, et al. Part 10: Adult and Pediatric Special Circumstances of Resuscitation: 2025 American Heart Association Guidelines for CPR and Emergency Cardiovascular Care. Circulation. 2025
AHA 2025 guideline: avoidance of sympathomimetics in hydrocarbon-mediated arrhythmia
Flanagan RJ, Ruprah M, Meredith TJ, Ramsey JD. An Introduction to the Clinical Toxicology of Volatile Substances. Drug Safety. 1990. PMID 2222869
Foundational toxicology; nitrite and solvent classification
Jupina M, Weleff J, Harp J, Anand A. Cognitive, Imaging, and Psychiatric Changes Associated With Chronic Toluene Use. Journal of Addictive Diseases. 2024. PMID 37503800
MRI findings in chronic toluene leukoencephalopathy; psychiatric co-morbidities
Nguyen J, O'Brien C, Schapp S. Adolescent Inhalant Use Prevention, Assessment, and Treatment: A Literature Synthesis. International Journal on Drug Policy. 2016. PMID 26969125
Kim J, Choe S, Shin I, et al. Analytical Methods for Detecting Butane, Propane, and Their Metabolites in Biological Samples. Journal of Chromatography B. 2024. PMID 38277722
GC-MS detection methods for volatile substance confirmation
Crossin R, Scott D, Witt KG, et al. Acute Harms Associated With Inhalant Misuse. Drug and Alcohol Dependence. 2018. PMID 29981942
Gender trends, co-morbidities, ambulance attendance data
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.